At the same time, B7H3/Dox@GNCs displayed the highest plasma half-life (T1/2, 21.32 ± 2.46 h) and mean residence time (MRT0-∞, 23.48 ± 2.06 h) among the tested formulations, confirming a longer circulation characteristic and suggesting that the surface modification with anti-B7H3 scFv may facilitate longer retention in the tumor. Here, CD276 is linked to neoplasm.